文献速递消化道肿瘤与早癌肝病

IL-10通过诱导PD-L1削弱抗肿瘤免疫并促进肝转移

IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction.
PubMed 文献 · J Hepatol · 2023-12-30

该研究在小鼠结直肠癌肝转移模型中探索IL-10的作用。发现Foxp3+ Treg是转移灶IL-10主要来源,IL-10以自分泌方式放大自身产生,并作用于单核细胞上调PD-L1,从而削弱CD8+ T细胞杀伤。缺失IL-10或阻断IL-10受体可减少肝转移。

要点

  • Treg来源的IL-10促进结直肠癌肝转移形成。
  • IL-10作用于单核细胞诱导PD-L1上调,抑制CD8+ T细胞抗肿瘤免疫。
  • 阻断IL-10/IL-10R或PD-L1/PD-1轴可减少肝转移,为联合免疫治疗提供依据。

核心结论

  • Treg来源的IL-10通过上调单核细胞PD-L1削弱CD8+ T细胞抗肿瘤免疫,促进结直肠癌肝转移。

研究设计与样本

  • 小鼠结直肠癌肝转移模型:盲肠注射MC38细胞或脾脏注射结肠肿瘤类器官。
  • 使用IL-10及IL-10受体α完全或细胞类型特异性敲除小鼠、PD-L1缺陷小鼠及IL-10报告小鼠。
  • 采用流式细胞术分析IL-10对PD-L1的调控。

主要发现

  • Il10缺陷小鼠及抗IL-10受体α抗体处理小鼠肝转移形成减少。
  • Foxp3+ Treg是肝转移灶IL-10的主要细胞来源;Treg特异性而非髓系特异性IL-10缺失减少肝转移。
  • IL-10以自分泌方式作用于Treg进一步放大IL-10产生。
  • IL-10作用于单核细胞上调PD-L1,PD-L1/PD-1轴削弱CD8依赖的细胞毒性。

临床怎么用

  • 在结直肠癌肝转移中可考虑监测IL-10水平,作为免疫治疗疗效的潜在生物标志物。
  • 靶向IL-10/IL-10R或PD-L1/PD-1轴可能改善结直肠癌肝转移的免疫治疗疗效。

局限性

  • 研究基于小鼠模型,人体临床转化需进一步验证。
  • 原文未报告IL-10或PD-L1在人体肝转移样本中的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The liver is one of the organs most commonly affected by metastasis. The presence of liver metastases has been reported to be responsible for an immunosuppressive microenvironment and diminished immunotherapy efficacy. Herein, we aimed to investigate the role of IL-10 in liver metastasis and to determine how its modulation could affect the efficacy of immunotherapy in vivo. METHODS: To induce spontaneous or forced liver metastasis in mice, murine cancer cells (MC38) or colon tumor organoids were injected into the cecum or the spleen, respectively. Mice with complete and cell type-specific deletion of IL-10 and IL-10 receptor alpha were used to identify the source and the target of IL-10 during metastasis formation. Programmed death ligand 1 (PD-L1)-deficient mice were used to test the role of this checkpoint. Flow cytometry was applied to characterize the regulation of PD-L1 by IL-10. RESULTS: We found that Il10-deficient mice and mice treated with IL-10 receptor alpha antibodies were protected against liver metastasis formation. Furthermore, by using IL-10 reporter mice, we demonstrated that Foxp3+ regulatory T cells (Tregs) were the major cellular source of IL-10 in liver metastatic sites. Accordingly, deletion of IL-10 in Tregs, but not in myeloid cells, led to reduced liver metastasis. Mechanistically, IL-10 acted on Tregs in an autocrine manner, thereby further amplifying IL-10 production. Furthermore, IL-10 acted on myeloid cells, i.e. monocytes, and induced the upregulation of the immune checkpoint protein PD-L1. Finally, the PD-L1/PD-1 axis attenuated CD8-dependent cytotoxicity against metastatic lesions. CONCLUSIONS: Treg-derived IL-10 upregulates PD-L1 expression in monocytes, which in turn reduces CD8+ T-cell infiltration and related antitumor immunity in the context of colorectal cancer-derived liver metastases. These findings provide the basis for future monitoring and targeting of IL-10 in colorectal cancer-derived liver metastases. IMPACT AND IMPLICATIONS: Liver metastasis diminishes the effectiveness of immunotherapy and increases the mortality rate in patients with colorectal cancer. We investigated the role of IL-10 in liver metastasis formation and assessed its impact on the effectiveness of immunotherapy. Our data show that IL-10 is a pro-metastatic factor involved in liver metastasis formation and that it acts as a regulator of PD-L1. This provides the basis for future monitoring and targeting of IL-10 in colorectal cancer-derived liver metastasis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Shiri AM, Zhang T, Bedke T, et al. IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction. J Hepatol. 2023. PMID: 38160941. doi:10.1016/j.jhep.2023.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。